Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
6.81
-0.18 (-2.58%)
At close: Sep 25, 2026, 4:00 PM EDT
6.80
-0.01 (-0.15%)
After-hours: Sep 25, 2026, 7:51 PM EDT
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
149
Market Cap
421.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
KYTX News
- 1 day ago - Kyverna Therapeutics Transcript: Study update - Transcripts
- 1 day ago - Kyverna Therapeutics Press release: Study update - Filings
- 1 day ago - Kyverna Therapeutics Slides: Study update - Filings
- 1 day ago - Kyverna Therapeutics Slides: Investor presentation - Filings
- 1 day ago - Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG - TheFly
- 1 day ago - Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis - GlobeNewsWire
- 10 days ago - Kyverna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 11 days ago - Kyverna Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts